CTLA4 and neoplasm: In contrast, patients with higher and lower than average levels of CTLA-4 expression demonstrated mean PFS times of 36.063 ± 7.923 months and 50.841 ± 13.335 months, respectively (p = 0.845); hence, CTLA-4 was not an indicator of tumor progression.